A patient diagnosed with narcolepsy is prescribed a psychomotor stimulant to manage their symptoms of overwhelming daytime sleepiness. What is the primary therapeutic goal of this medication for this specific condition?

Given the following case study, explain the therapeutic rationale for prescribing a psychomotor stimulant.

Narcolepsy Treatment Rationale

Psychomotor stimulant drugs, such as amphetamines, are a primary treatment for narcolepsy. These medications function by increasing overall levels of neural activity to combat daytime sleepiness. Examples include modafinil, armodafinil, and various amphetamines.

Google

Scripps College

University of Rochester

The study of the effects of drugs on the brain and behavior.

Psychopharmacology 

People with narcolepsy can differ substantially in how their symptoms appear and in how well available treatments work. McCarty's case study illustrates this variability: a 50-year-old woman had excessive sleepiness during waking hours, unusual right-sided cataplexy, no dream-like hallucinations, little improvement with a stimulant alone, and major improvement when the stimulant was paired with an antidepressant.

Variability in Narcolepsy Symptoms and Treatment Response

Mayo Foundation for Medical Education and Research. (2020, November 6). Narcolepsy. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/narcolepsy/diagnosis-treatment/drc-20375503. 

Mayo Clinic Narcolepsy

Spielman, R. M., Jenkins, W. J., & Lovett, M. D. (2020, April 22). Psychology (2nd ed.). OpenStax. https://openstax.org/books/psychology-2e/pages/1-introduction

OpenStax Psychology (2nd ed.) Textbook

Psychopharmacology Library

Microdosing is the administration of a psychedelic drug/medication at one-tenth of the dose that would cause hallucinogenic effects.

Microdosing

Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs used to treat conditions like depression, which is often associated with low serotonin levels. Unlike agonists or antagonists that bind to receptors, SSRIs work by blocking the reuptake process. This action prevents unused serotonin from being reabsorbed by the presynaptic neuron, allowing it to remain in the synaptic cleft for a longer period. The extended presence of serotonin enhances its interaction with postsynaptic receptors, thereby strengthening its overall effect. Common examples of SSRIs include Prozac, Paxil, and Zoloft.

SSRIs and SNRIs

A class of drugs that typically alleviate symptoms of schizophrenia. (Also called neuroleptics)

- The Dopamine Hypothesis

- Typical Antipsychotics

- Long-Term Effects of Antipsychotic Drugs

- Atypical Antipsychotics

- The Glutamate Hypothesis

Antipsychotic Drugs

Tricyclic (or heterocyclic) antidepressants inhibit the reuptake of serotonin and/or norepinephrine, and are thus called due to their three (or more)-ring chemical structure. Some examples include:

- Amitriptyline (Elavil) 
- Nortriptyline (Aventyl)
- Maprotiline hydrochloride (Ludiomil)
- Desipramine hydrochloride (Norpramin)
- Clomipramine (Anafranil)

A similar drug is Bupropion (Wellbutrin), which is an aminoketone that weakly blocks norepinephrine, serotonin, and dopamine reuptake.

Tricyclic Antidepressants

MAOIs inhibit the breakdown of the enzyme that breaks down monoamine neurotransmitters. Some MAOIs have antidepressant effects, including:

- Phenelzine (Nardil)
- Isocarboxazid (Marplan)
- Tranylcypromine (Parnate)

Monoamine Oxidase Inhibitors (MAOIs)

Psychoplastogens class of compounds that take effect on neural plasticity in key circuits involved in brain health. Psychoplastogens include psychadelics, and produce a quantifiable change in plasticity within a short time frame (>72 h) post administration.

Psychoplastogens 

The study of the use of extracts and compounds obtained from mushrooms as medicines or health-promoting agents. Mycotherapy, also known as fungal or mushroom therapy, is a branch of natural medicine exploring the therapeutic properties and potential health benefits of various mushrooms. The practice of using mushrooms for medicinal purposes has been observed in different cultures throughout history, and it continues to gain recognition and scientific interest in modern times.

Mycotherapy

Medications that have Anticholinergic effects are associated with central and peripheral side effects. These include constipation, confusion, sedation, and dry mouth. Increased Anticholinergic exposure increases adverse risks.

Anticholinergic Medicines

Stimulants for Narcolepsy

These older antidepressants can be helpful for alleviating cataplexy. Side effects include dry mouth and lightheadedness. 

Tricyclic antidepressants

This medication is very effective in treating cataplexy and improving nighttime sleep. In higher doses, it may also help with daytime sleepiness. It needs to be taken at bedtime and four hours later though, so it can be inconvenient in this sense. Side effects include nausea, bedwetting, and sleepwalking. Taking this with other sleep medications, narcotic pain relievers, or alcohol can be incredibly dangerous. 

Sodium oxybate (Xyrem)

Recently approved Treatments for Narcolepsy

Traditional stimulant medications used to treat narcolepsy do not directly affect the hypocretin system, a key signaling pathway that is deficient in individuals with the disorder. Consequently, it is anticipated that new medications will be developed to specifically target and act upon the hypocretin system to provide more effective treatment.

Future of Narcolepsy Medication: Targeting the Hypocretin System

McCarty's (2010) case study describes a 50-year-old woman who was diagnosed with narcolepsy after sleep testing. She had experienced excessive sleepiness during normal waking hours for several years and had fallen asleep in inappropriate or dangerous situations, including while eating, socializing, and driving. During emotional arousal, she experienced unusual right-sided cataplexy but did not have dream-like hallucinations. A stimulant alone was not successful, but combining the stimulant with an antidepressant led to dramatic improvement.

Case Study of Narcolepsy: Symptom Variability and Combination Therapy

A patient diagnosed with narcolepsy begins treatment with a standard psychomotor stimulant. After a month, they report that their excessive daytime sleepiness has only slightly improved, and they still experience frequent episodes of sudden muscle weakness triggered by laughter. Based on the typical challenges in treating this condition, what is the most appropriate next step for the healthcare provider to consider, and what is the underlying reason for this strategy?

Learn Before

Related

Learn After